|
| Status |
Public on Aug 12, 2020 |
| Title |
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms’ tumor cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We have undertaken a functional genomics approach to uncover novel therapeutic strategies efficacious for those patients with anaplastic Wilms’ tumor. Genomic analysis, in vitro chemical screens and microfluidic experiments demonstrate that MYCN over-expression in Wilms’ tumor can be modulated via BRD4 inhibition resulting in a reduction in Wilms’ tumor cell growth.
|
| |
|
| Overall design |
Transcriptome analysis, in vitro chemical screens and microfluidic experiments demonstrate that MYCN over-expression in Wilms’ tumor can be modulated via BRD4 inhibition resulting in a reduction in Wilms’ tumor cell growth.
|
| |
|
| Contributor(s) |
Woods AD, Berlow NE, Lathara M, Michalek JE, Wright H, Royer-Pokora B, Veselska R, Keller C |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| Submission date |
Aug 11, 2020 |
| Last update date |
Dec 02, 2020 |
| Contact name |
Charles Keller |
| E-mail(s) |
charles@cc-tdi.org
|
| Phone |
8012328038
|
| Organization name |
cc-TDI
|
| Department |
Pediatric Cancer Biology
|
| Street address |
12655 Sw Beaverdam Rd West
|
| City |
Beaverton |
| State/province |
Oregon |
| ZIP/Postal code |
97005 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA656572 |
| SRA |
SRP277098 |
Less...
More...